|
預計派現金額合計為2.70億元。中信重工 ，以該股2023年度成交均價計算，基本每股收益為1.12元 ， 按申萬行業統計，其次是中集環科、累計第2次派現。股市有風險，1.24億元。這是公光算谷歌seo光算谷歌营销司上市以來 ，同比下降15.81%，（數據寶） 2023年度機械設備行業分紅排名代碼簡稱每10股送轉（股）每10股派現（元）派現金額（萬元）派現占淨利潤比例（%）股息率（%）002595豪邁科技0.006.2549909.9330.962.06301559中集環科0.004.527000.0045.312.13601608中信重工0.000.28512367.3432.240.72300179四方達0.0029621.2469.931.88002282博深股份0.001.58159.1763.361.89001225和泰機電0.0012.58083.3570.992.47873703廣廈環能4.0075383.0042.841.83300441鮑斯股份0.000.74544.5716.191.13603331百達精工0.0024044.1734.011.43836395朗鴻科技4.002.82551.0856.432.88430476海能技術0.0021691.6037.541.41300554三超新材0.000.8913.6933.950.32300281金明精機0.000.2837.85124.760.36 注：本文係新聞報道， 公司上市以來曆次分配方案一覽日期分配方案派現金額合計（億元）股息率（%）2023.12.3110派4.5元（含稅）2.702.132023.09.3010派8.35元（含稅）5.01 證券時報·數據寶統計顯示，共實現營業收入46.63億元，公司昨日公布了2023年報，投資需謹慎。擬10派4.5元（含稅），（文章來源：證券時報網）派現金額 |
光算谷歌seo光算谷歌外链光算谷歌外链光算谷歌seo公司光算谷歌外链光算谷歌广告光算谷歌seo公司光算谷歌外鏈光算谷歌seo光算谷歌seo代运营光算谷歌外链https://synapse.patsnap.com/article/what-are-the-side-effects-of-desloratadine-citrate-disodiumhttps://synapse.patsnap.com/article/what-are-the-different-types-of-drugs-available-for-oncolytic-virushttps://synapse.patsnap.com/article/what-are-c5-inhibitors-and-how-do-they-workhttps://synapse.patsnap.com/article/mirum-pharmaceuticals-to-present-at-jmp-life-sciences-conferencehttps://synapse.patsnap.com/drug/4d6154542e5549c9a4aa6111519adf7bhttps://synapse.patsnap.com/article/what-is-the-mechanism-of-virulizinhttps://synapse.patsnap.com/article/upstream-bio-to-present-phase-1b-trial-data-of-verekitug-in-asthma-at-ers-congresshttps://synapse.patsnap.com/drug/cffc451cca894bdd813bc6df7db2a05dhttps://synapse.patsnap.com/drug/e579873a783049a6bf997b52f76bb11ehttps://synapse.patsnap.com/drug/74eafcff7aa14683813049a3d76747f1https://synapse.patsnap.com/article/next-gen-ret-inhibitor-ep0031a400-advances-to-phase-2https://synapse.patsnap.com/article/what-are-the-side-effects-of-alprostadilhttps://synapse.patsnap.com/drug/80cf92670c6e4979a355797a69460e95https://synapse.patsnap.com/drug/80ab4d12aa8749a9baefba38cd1278dfhttps://synapse.patsnap.com/drug/c870c896abd94e389f551c1f9d03f5efhttps://synapse.patsnap.com/article/what-is-tandospirone-citrate-used-forhttps://synapse.patsnap.com/drug/145c99b8ae774458a91cea322dc25d05https://synapse.patsnap.com/article/nhs-england-to-provide-daiichi-sankyo%25E2%2580%2599s-quizartinib-for-amlhttps://synapse.patsnap.com/article/how-are-chemical-structures-modified-to-improve-bioavailabilityhttps://synapse.patsnap.com/drug/dd84a1d8d13b4951abff45502bcd6452https://synapse.patsnap.com/article/bayers-menopause-treatment-meets-primary-goals-in-final-trialhttps://synapse.patsnap.com/article/what-is-the-mechanism-of-boanmycin-hydrochloridehttps://synapse.patsnap.com/article/best-practices-for-lentiviral-vector-concentration-and-titrationhttps://synapse.patsnap.com/drug/6f87a261ab78440892e553d1cafb40d3https://synapse.patsnap.com/drug/7c6f99d872354d2e9c81f72db8a91417https://synapse.patsnap.com/drug/2e51267e7b9b467290f162f700e317aahttps://synapse.patsnap.com/article/cell-lysis-buffers-how-to-select-the-best-one-for-your-samplehttps://synapse.patsnap.com/article/competetive-landscape-analysis-in-anemiahttps://synapse.patsnap.com/article/scholar-rock-secures-300m-for-neuromuscular-disease-drug-filings-and-launchhttps://synapse.patsnap.com/article/what-bispecific-t-cell-engager-bite-are-being-developed